Interim report of phase II study of new nitrosourea S 10036 in disseminated malignant melanoma.
Thirty-three patients with disseminated malignant melanoma were entered in a phase II study of the new nitrosourea S 10036 using a 100-mg/m2 weekly induction schedule for 3-4 consecutive weeks. Patients who responded to this treatment were followed with a maintenance therapy every 3 weeks. Toxic effects were mainly hematological and consisted of delayed thrombocytopenia and leukopenia. Among 30 patients who could be evaluated, eight partial responses were observed (response rate, 26.67%); among seven patients with cerebral metastasis, two partial responses were observed. This multicentric study is currently being continued to confirm this interim report.
Khayat
D
D
Service d'Oncologie Médicale, Hôpital La Pitié Salpêtrière, Paris, France.
Bizzari
J P
JP
Frenay
M
M
Naman
H
H
Weil
M
M
Goupil
A
A
Namer
M
M
Rouesse
J
J
Banzet
P
P
Jacquillat
C
C
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; C054368:fotemustine